Drew Dunnington

Vice President

Tim Eber

Associate

Paras Mehta Ph.D

Chief Investment Officer

Weitz, Rob

Managing Director

6 past transactions

Rocky Mountain Recreation Company provide management services to campgrounds, marinas, day use areas and other recreation sites for Federal, State and Local Agencies.

Jaguar Gene Therapy

Series B in 2021
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

Taysha Gene Therapies

Series B in 2020
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.

Encoded Therapeutics

Series D in 2020
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.

Palvella Therapeutics

Series C in 2020
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

Taysha Gene Therapies

Seed Round in 2020
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.